Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer  by Parnes, Eliezer L. & Shapiro, Warren B.
Kidney International, Vol. 40 (1991), pp. 1148—1152
Anaphylactoid reactions in hemodialysis patients treated with
the AN69 dialyzer
ELIEZER L. PARNES and WARREN B. SHAPIRO
Division of Nephrology and Hypertension, The Brookdale Hospital Medical Center, Brooklyn, New York, USA
Anaphylactoid reactions in hemodialysis patients treated with the AN69
dialyzer. During an ii week period (May to July, 1990), we observed six
anaphylactoid reactions (AR) in six different hemodialysis patients
occurring at the onset of treatment with a new AN69 hollow-fiber
dialyzer. Four patients required cardiopulmonary resuscitation and one
of these expired. Four patients were also receiving an angiotensin
converting enzyme (ACE) inhibitor while the other two were not on
medication known to affect the renin-angiotensin system. Only patients
treated with AN69 dialyzers were affected. A review of the literature
indicated that out of 1087 patients reported, 72 patients were on the
combination of an AN69 dialyzer and ACE inhibitor therapy and 41
(57%) demonstrated AR. Only two patients (0.4%; both from our series)
treated with an AN69 dialyzer without ACE inhibitor therapy devel-
oped AR. AR did not occur in patients treated with a variety of other
dialyzers during this 11 week period, with or without ACE inhibition.
Possible causes for AR are discussed and include: (1.) blood-AN69
membrane interaction leading to the production of bradykinin and other
vasodilators, the breakdown of which may be delayed by the presence
of ACE inhibitors; (2.) hypersensitivity to ethylene oxide; (3.) passage
of bacterial products from dialysate to blood; (4.) changes in membrane
manufacturing specifications. Recommendations are proposed for the
prevention and treatment of AR.
Acute anaphylactoid reaction (AR) occurring during hemodi-
alysis, although rare, can be life threatening [1, 2]. Signs and
symptoms include urticaria, angioedema, dyspnea, broncho-
spasm, hypotension, cardiovascular collapse and death [2, 3].
The incidence of AR severe enough to require discontinuation
of dialysis was 3.5 per 100,000 dialyzers sold in 1982 [1], and is
most frequently associated with capillary dialyzers made of
cuprammonium cellulose [4—6], although AR has also been
reported with plate and coil dialyzers made of cuprammonium
acetate and polyacrylonitrile (PAN) [2, 7], and in plasma donors
probably related to the tubing set used [1]. Recently, two papers
from Belgium described a total of 12 patients with severe AR
(including hypotension and bronchospasm), during treatment
with a hollow fiber, PAN membrane dialyzer (AN69, Hospal
Corporation Lyon, France) while taking an ACE inhibitor [8,
9]. During an 11 week period (May to July, 1990), we observed
six episodes of AR manifested by hypotension (systolic blood
pressure below 90 mm Hg) requiring normal saline and/or
colloid infusions in six different patients. All of these patients
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were dialyzed on single use AN69 dialyzers from several
different lots. Four of the six were also taking an ACE inhibitor
while the other two were not on medication known to affect the




D.M. is a 40-year-old Black female with ESRD secondary to
diabetic nephropathy who has been on hemodialysis since 4/90.
On 5/8/90 she underwent her fourth hemodialysis treatment
with an AN69 hollow fiber dialyzer (Hospal Inc., Lakewood,
Colorado, USA). Immediately after starting dialysis she com-
plained of "not feeling well", lost consciousness and suffered a
cardiopulmonary arrest from which she was successfully resus-
citated. She was subsequently treated with a Toray B1-1.2U
hollow-fiber dialyzer (Toray Inc., New York, New York, USA)
which utilizes a gamma sterilized, polymethylmethacrylate
(PMMA) membrane. No further episodes of hypotension were
noted even though the patient was switched again to an ethyl-
ene oxide sterilized, polysulfone, Fresinius F-80 dialyzer
(Fresinius U.S.A., Concord, California, USA) and remained
asymptomatic. Medications at the time of the cardiac arrest
included: nifedipine, calcitriol, calcium carbonate and NPH
insulin.
Case 2
R.M. is a 72-year-old Black female with ESRD secondary to
diabetic nephropathy and hypertension. The patient had been
dialyzed since 2/90 utilizing an AN69 dialyzer. On 5/24/90,
during her 36th treatment, she complained of dizziness and
nausea followed by vomiting immediately after starting dialysis
(blood flow 200 ml/min). The blood pressure fell to 80 mm Hg by
palpation. Dialysis was interrupted until blood pressure was
normalized with normal saline infusion. Dialysis was subse-
quently resumed with an ethylene oxide sterilized cellulose
acetate CA-2 10 dialyzer (Travenol Corporation, Round Lake,
Illinois, USA). In all subsequent dialysis treatments this dia-
lyzer was used with no further AR. Medications at the time of
the episode were: captopril, isosorbide dinitrate, transdennal-
nitroglycerin, docusate sodium and lactulose.
Case 3
L.S. was a 51-year-old Black female with ESRD secondary to
diabetic nephropathy and hypertension treated with dialysis
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Table 1. Clinical parameters and outcome of patients exhibiting AR
No.
Case




dialysis Symptoms Medications Outcome





















5 6/16/90 DM 70 B M 17 <10 mm Shock respiratory
arrest
NPH insulin Recovered




Abbreviations are: C, captopril; E, enalapril; Ca CH. BL., calcium channel blocker.
First treatment at Brookdale Hospital after transfer from satellite unit
since 1/86. She had originally been treated with CAPD, but a
recent cerebrovascular accident and recurrent peritonitis neces-
sitated transferring her to hemodialysis. She was afebrile and
had no symptoms of peritonitis. Immediately after starting her
18th treatment utilizing an AN69 dialyzer, she complained of
"feeling sick" and her blood pressure fell to 70 mm Hg by
palpation. Three hundred ml of normal saline were rapidly
infused, but cardiac arrest ensued and the patient expired. Her
medications included: captopril, vancomycin, aminoglycoside
antibiotic, clonidine, ranitidine hydrochloride, isosorbide dini-
trate and insulin.
Case 4
L.C. is a 56-year-old Hispanic male with ESRD secondary to
hypertensive nephrosclerosis. He received his dialysis at an-
other unit which used a cellulose acetate dialyzer until 6/8/90,
when he was admitted to The Brookdale Hospital Medical
Center because of an acute inferior wall myocardial infarction.
He received peritoneal dialysis during the pen-infarction pe-
riod. On 6/14/90, while receiving his first hemodialysis, he
complained of itching and nausea followed by hypotension (80
mm Hg systolic) upon initiation of dialysis with an AN69
dialyzer. Respiratory distress ensued, necessitating intubation.
His blood pressure was restored to 120/80 with normal saline.
No arrhythmias or signs of infarct extension were noted. During
subsequent hemodialysis treatments, the Toray Bl-l.2U dia-
lyzer was used without further incident. Medications at the time
of the hypotensive event included: enalapnil maleate, isosorbide
dinitrate, metoprolol tartrate, aluminum containing antacids,
docusate sodium, subcutaneous heparin and acetominophen.
Case 5
C.B. is a 70-year-old Black male who has been on hemodial-
ysis since 2/89 secondary to diabetic nephropathy. He had been
receiving his dialysis therapy at a satellite unit (utilizing cellu-
lose acetate dialyzers sterilized with ethylene oxide) and was
transferred back to The Brookdale Hospital Medical Center for
treatment due to deteriorating cardiovascular status. He was
treated with both AN69 and cellulose acetate (CA 210) dialyzers
without incident. On 6/16/90 (treatment #17), less than 10
minutes into the treatment with an AN69 dialyzer, he was noted
to be unresponsive with a systolic blood pressure of 70 mm Hg
by palpation and required endotrachial intubation. The patient
was successfully resuscitated. No arrhythmia was noted, nor
were there any signs of myocardial ischemia on the EKG. The
dialyzer was changed to a CA 210 and treatment resumed
without further complication. The patient's medications in-
cluded: NPH insulin, calcium carbonate and diphenhydramine
hydrochloride.
Case 6
E.J. is a 71-year-old Black female with ESRD secondary to
hypertensive nephrosclerosis who had been on hemodialysis
since 4/88, recently treated with a cellulose acetate dialyzer at a
satellite unit. On 7/19/90 she was admitted to The Brookdale
Hospital Medical Center for revision of her angio-access, and
was taking the following medications: enalapril maleate, cloni-
dine, metoprolol tartrate, nifedipine, acetominophen and tniaz-
olam. Immediately after starting dialysis with an AN69 dia-
lyzer, she vomited and became diaphoretic and hypotensive
(systolic blood pressure 60 mm Hg). Her blood pressure was
supported with normal saline and dialysis resumed using a
CA-2l0 dialyzer. The patient required normal saline and hyper-
oncotic albumin throughout the treatment to keep her blood
pressure stable. During subsequent hemodialysis treatments,
CA-2l0 dialyzers were used and no further episodes of hypo-
tension occurred during this hospitalization. Of note, she was
readmitted to the hospital during 11/90 for further revision of
her access and received three dialysis treatments with the AN69
dialyzer while on the same dose of the ACE inhibitor without
incident.
The six patients with AR are summarized in Table 1. Five of
the six patients were Black and one was Hispanic. There were
four females and two males. Four patients were diabetic, two of
whom were taking NPH insulin. Two patients (#4 and #6) were
treated for the first time at our hospital and to our knowledge
had not previously been exposed to an AN69 dialyzer. Patient
I had undergone three previous treatments on AN69. During
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her third dialysis she developed easily controlled hypotension
toward the end of treatment. The other three patients were also
relatively new to dialysis, having had 16, 17 and 35 treatments
prior to the AR. In patient #4 allergic symptoms of itching
occurred prior to vascular collapse. Two patients (#1 and #3)
developed cardiac arrest, one of whom died (#3), and two
additional patients (#4 and #5) required endotrachial intubation
secondary to respiratory arrest. In five patients the AR was
immediate, occurring in the first minute of dialysis as the blood
was being returned from the dialyzer to the patient. In the
remaining patient (#5) the episode occurred a little later, but
less than 10 minutes after starting the treatment. Four of the six
patients were taking an ACE inhibitor (2 captopril, 2 enalapril)
at the time of the AR. In all cases, the ACE inhibitor had been
started at least 10 days prior to the AR. Three of the four
patients on ACE inhibition were also taking long acting nitrates.
In no case was there a recent change either in the type or dose
of any medication. ACE inhibition therapy was continued in the
three surviving patients.
None of the five surviving patients has had a second AR. Two
patients (#1 and #6) were changed to PMMA, gamma irradi-
ated dialyzers for subsequent treatments. Patient #1 was later
changed to a polysulfone dialyzer sterilized with ethylene
oxide. The remaining three patients were changed to cellulose
acetate dialyzers, sterilized with ethylene oxide. Of interest,
several weeks after the AR, patient #6 received three treat-
ments on an AN69 dialyzer without incident while taking an
ACE inhibitor.
The records of all patients receiving hemodialysis at The
Brookdale Hospital Medical Center during the 12 week period
of May 1, 1990 to July 31, 1990 were reviewed. In this time
period 152 patients were treated, 131 with AN69, and 21 with
other dialyzers including cellulose acetate, polysulfone and
PMMA. Seventeen patients treated with the AN69 dialyzer
were on an ACE inhibitor, four of whom (23%) developed AR.
Eight patients receiving ACE inhibition while on other dialyzers
had no episodes of AR. Of those patients not receiving an ACE
inhibitor, two out of 114 (1.8%) treated with AN69 dialyzers
developed AR, while none of the 13 patients treated with other
dialyzers had AR.
Discussion
In this report, six patients receiving hemodialysis using an
AN69 membrane experienced an AR, of which four required
cardiopulmonary resuscitation and one died. Four of the six
were receiving concomitant treatment with an ACE inhibitor.
To our knowledge this represents the first report of an adverse
reaction to this combination of medication and dialyzer in the
United States, and the first reported AR to AN69 dialyzers in
the absence of an ACE inhibitor.
In Europe, Tielemans et al [8] first reported five severe
episodes of AR in three patients treated with ACE inhibition
and the AN69 membrane. Two patients had mild symptoms of
allergy during one dialysis treatment followed by severe AR
with hypotension at the start of the following treatment. Since
that original paper there have been several reports and letters
describing similar episodes [9—131. We have combined our data
with those of five centers in Europe (Table 2). Out of a total of
1087 patients reported, 591 were dialyzed with an AN69 dia-
lyzer, and 496 with a variety of cellulosic and non-cellulosic
Table 2. Review of recent reports of AR during AN69 dialysis
ACE inhibitor No ACE inhibitor
1St Author Other Other
[reference #] Reaction AN69 dialyzers AN69 dialyzers
Tielemans [8] Present 3 0 0 0
Absent 1 9 19 43
Tietemans [11] Present 11 0 0 0
Absent 5 54 82 369
Alvarez- Present 4 — 0 —
Lara [10] Absent I — 29 —
Jadoul [12] Present 10 — — —
Absent 3 — — —
Verreson [9]a Present 9 — 0 —
Absent 8 — 275 —
Brookdale Present 4 0 2 0
Absent 13 8 112 13
Total reactions present 41(57%) 0 2 (0.4%) 0
Total patients 72 71 519 425
a Includes 56 patients on hemofiltration
dialyzers. An AN69 dialyzer plus ACE inhibition was noted in
72 patients, 41 of whom had AR (57%). Of 519 patients treated
with AN69 without ACE inhibition, two patients (from our
series; 0.4%) had AR. No patient treated with any of the other
dialysis membranes had AR, either with (71 patients) or without
(425 patients) concomitant ACE inhibition.
ACE inhibitors block the conversion of angiotensin I to
angiotensin II and are used for the treatment of hypertension
and congestive heart failure. Kininase II, an enzyme widely
distributed in the body which degrades the potent vasodilator,
bradykinin, is identical to ACE. The use of ACE inhibitors
results in the accumulation of kinins and the enhancement of
kinin activity in vivo [14, 15] which may be responsible, in part,
for their hypotensive effects. Enhanced bradykinin activity, in
turn, increases prostaglandin synthesis, and it has been shown
that captopril increases circulating plasma levels of PGE2,
another potent vasodilator [16]. ACE is also involved, in part,
in the degradation of the tachykinin, substance P. which can
cause vasodilitation, hypotension and smooth muscle contrac-
tion and which is elevated after ACE inhibition [161. ACE
inhibitors have also been shown to increase allergen induced
histamine release from skin mast cells in the guinea pig [17].
One of the side effects of ACE inhibitor therapy (regardless of
renal function) is the development of spontaneous angioedema
with swelling of the face, lips, tongue, glottis and extremities
associated with urticaria [18], signs similar to those described in
one of our patients with AR. The incidence of spontaneous
angioedema associated with ACE inhibitor use is between 0.1
and 0.2%, usually occurring within the first month of therapy,
but also seen later on in treatment and more frequently with the
long acting agents, lisinopril and enalapril [18, 19]. A review of
our data plus those available from the literature [8—10] showed
no difference in the incidence of AR in patients taking captopril
(7 patients) versus lisinopril (2 patients) and enalapril (11
patients). Recently, four patients with a prior history of idio-
pathic angioedema were reported to have had severe angio-
edema related to ACE inhibitor therapy [14]. None of our
patients and none of the patients with AR described in the
literature were noted to have idiopathic angioedema.
Why should AR occur only in patients treated with an AN69
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dialyzer and what role does concomitant ACE inhibitor therapy
play in this unique syndrome? Jadoul et a! [12] report a single
patient with repeated anaphylactoid reactions to the AN69
dialyzer. Reactions took place within five minutes of blood-
membrane contact when new dialyzers were used. It is known
that reprocessing of dialyzers with formalin results in a lower
incidence of allergic reactions compared to new dialyzers. This
presumably occurs because plasma proteins which may have
coated the membrane during the first use are not removed by
formalin, resulting in decreased blood-membrane reactivity
[20]. For example, formalin reprocessed cuprammonium cellu-
lose (Cupraphan) dialyzers showed only 20% of the comple-
ment activation of new dialyzers [20]. When the patient de-
scribed by Jadoul et al [121 was treated with a formalin
reprocessed AN69 dialyzer, AR did not occur. When hypochlo-
rite, an agent known to remove the protein coating from the
membrane was used, however, AR recurred at the same rate as
for new dialyzers.
One explanation for the increased incidence of AR with the
combination of ACE inhibitor and the AN69 dialyzer may be
related to the negative charge on that membrane [211. Nega-
tively charged surfaces are known to activate Hageman factor
[21], which in turn may result in stimulation of the kallikrein-
kinin cascade resulting in increased production of bradykinin
[22]. Once the kinin cascade is activated, the presence of an
ACE inhibitor may result in decreased degradation of bradyki-
nm with resultant hypotension. As discussed above, ACE
inhibition can also lead to delayed breakdown of substance P,
increased histamine release and elevated levels of PGE2, all of
which could contribute to hypotension. The occurrence of AR
in two of our patients not on an ACE inhibitor suggests that
other pathogenic mechanisms may be operative, and empha-
sizes the need for further study of the interaction of blood with
this membrane.
There is a possibility that the AR may have been caused by a
hypersensitivity reaction to ethylene oxide. Some patients
developing AR at the onset of a dialysis treatment were found to
have higher levels of IgE antibodies to ethylene oxide-altered
human serum albumin than asymptomatic patients [23]. Al-
though we have not tested our patients for antibodies to
ethylene oxide, in the first two reports of AR by Tielemans et a!
[8] and Verresen et al [9] these antibodies were not found.
Furthermore, Alvarez-Lara et al reported no amelioration of
AR in four patients who were changed from ethylene oxide
sterilized AN69 dialyzers to gamma irradiated AN69 dialyzers
[10]. In our study, four of five patients were continued on
ethylene oxide-sterilized equipment (dialyzers and tubing) with
no further complications, thus suggesting that this agent was
unlikely to be responsible for the AR.
High-flux dialyzers such as the AN69 have increased perme-
ability for large molecular weight substances and may be
beneficial in removing potentially deleterious compounds such
as /32-microglobulin [24]. This same property may be disadvan-
tageous as bacterial products from the dialysate may be able to
cross the dialyzer and activate cytokines in the patient's blood
[25]. Verresan et al [9] suggested that bacterial products may
have been responsible for the AR described in their patients;
however, Dinarello [26] points out that bacterial products
crossing the membrane may result in endotoxic shock charac-
terized by delayed hypotension and fever as opposed to ana-
phylactic shock, which is immediate and rarely associated with
fever. The hypotensive episodes in our patients more closely
resembled an anaphylactic reaction, since they occurred early
in the treatment and were not associated with fever. Addition-
ally, since dialysate for an entire shift (11 patients) is made at
one time and the six episodes described were isolated occur-
rences, dialysate contamination would appear to be an unlikely
explanation for the hypotensive episodes in our patients.
Changes in the manufacturing process for AN69 dialyzers
may have taken place during or prior to the 11 week period
described, perhaps exposing the patients to a new chemical
agent. It is of interest that our report in the USA and those of
Alverez and Tielmans in Europe describe patients treated late
in 1989 through 1990 [8, 10, 11], however, the Hospal Corpo-
ration states that no change in the manufacturing process has
taken place within the last two years (personal communication,
Hospal, France).
In all cases of AR reported, switching to a non-AN69 dialyzer
with continuation of ACE inhibitor therapy or maintenance of
AN69 treatment while stopping the ACE inhibitor resulted in
disappearance of AR [8—13]. All of our patients were switched
to other dialyzers and ACE inhibition continued with no recur-
rence of AR. Therefore, we would recommend that in patients
taking an ACE inhibitor, other dialyzers be selected, or that
alternative medications be considered if dialysis with AN69 is
contemplated.
In summary, we have presented six cases of AR occurring in
six patients treated with the AN69 dialyzer, four of whom were
also receiving an ACE inhibitor. The possible pathogenesis is
discussed and the literature reviewed. Although the exact
pathogenesis of this unique syndrome is not known, it is
apparent that the combination of AN69 plus ACE inhibitor has
the potential to cause profound hypotension and death. In two
patients, similar AR developed during dialysis with an AN69
dialyzer in the absence of ACE inhibition. Termination of either
the ACE inhibitor or the AN69 dialyzer is the best method of
prevention. Should an AR occur we would recommend: (1.)
clamping the blood lines immediately to prevent the return of
any additional blood to the patient; (2.) infusion of normal saline
at a rapid rate until the blood pressure is restored and/or
administration of pressor agents; (3.) intubation may be neces-
sary for oxygenation and or pulmonary toilet; (4.) use of
epinephrine and glucocorticoids may be necessary if symptoms
of anaphylaxis persist.
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